Key Highlights

● IDEXX Laboratories closed at $560.36 on October 16, trading below the analyst target.

● The consensus 12-month price target is $702.38, implying about 25.3% upside.

● Analysts are split 9 Buy, 5 Hold, and 1 Sell on the stock.

● Targets range from $470 to $805 across 15 analysts.

IDEXX Laboratories (NASDAQ:IDXX), a member of the S&P 500 and the Nasdaq-100, closed at $560.36 on October 16, 2026, up 2.41%. The mean analyst target of $702.38 implies upside of about 25.3%, according to market data. The veterinary diagnostics group has seen several new coverage initiations and target changes in recent days.

What Is the Latest Analyst Price Target?

Fifteen analysts contribute to the consensus. The mean target is $702.38 and the median $710. The high is $805 and the low $470, which is about 16% below the latest price. The consensus target suggests sizeable upside, although the shares remain well below the 52-week high of $769.98.

What Are Analysts Saying?

The consensus rating is Buy, with nine analysts at Buy or Strong Buy, five at Hold and one at Sell. J.P. Morgan reiterated Buy but lowered its target to $750 from $775 on 16 October. KeyBanc initiated coverage with a Sector Weight (Hold) rating on 12 October, while Goldman Sachs initiated with a Buy. UBS held a Hold at $670 and Bank of America a Hold at $665 on earlier dates. Barclays had earlier lowered its target to $710 from $800.

What Could Help the Stock Reach the Price Target?

Second-quarter earnings per share of $4.27 beat the $3.93 consensus, according to the source. The acquisition of CoVetAI and expansion of its Faecal Dx platform in the UK may support recurring diagnostics demand. If testing volumes and pricing remain resilient, the shares could narrow the gap to the consensus.

What Could Prevent the Stock Reaching the Target?

The market capitalisation of about $44 billion is some 14% lower than a year ago, and several brokers have been trimming targets. Slower veterinary visit growth, pricing pressure or competition could weigh on earnings, and the mixed ratings from KeyBanc, UBS and Bank of America highlight valuation concerns.

What Should Investors Watch Next?

IDEXX is due to report third-quarter 2026 results on November 2, 2026. Investors may watch clinical visit trends, guidance and further analyst revisions.

A Target Worth Chasing

The consensus target of $702.38 lies about 25.3% above the latest close, with a Buy consensus from a relatively small group of 15 analysts. If the consensus proves accurate, upside would be material; however, forecasts are uncertain.